RAD51
Inhibitory Selectivity
RAD51 Products
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S1244 |
Amuvatinib (MP-470)Amuvatinib (MP-470, HPK 56) is a potent and multi-targeted inhibitor of c-Kit, PDGFRα and Flt3 with IC50 of 10 nM, 40 nM and 81 nM, respectively. Amuvatinib suppresses c-MET and c-RET. Amuvatinib is also active as a DNA repair protein Rad51 inhibitor with antineoplastic activity. Phase 2. |
Inactivation of AXL by MP470 reverses epithelial to mesenchymal transition. Immunoblot analyses of lysates from TGFβ/TNFα- treated MCF10A cells treated with varying amounts of MP470 for 72 hours.
|
|
| S2871 |
T0070907T0070907 is a potent and selective PPARγ inhibitor with IC50 of 1 nM in a cell-free assay, with a >800-fold selectivity over PPARα and PPARδ. T0070907 significantly decreases the levels of DNA-PKcs and RAD51 proteins in ME-180 and SiHa cells. |
Knocking down LKB1 reversed the PPARc antagonist T0070907-induced changes in the protein expression of the M1 markers (iNOS, green) and the M2 markers (CD206, red) by immunofluorescence staining. Scale bar = 20 μm.
|
|
| S8077 |
RI-1RI-1 (RAD51 inhibitor 1) is a RAD51 inhibitor with IC50 ranging from 5 to 30 μM. |
Inhibition of Rad51 sensitizes PTEN-WT BT549 cells to olaparib. A. Immunofluorescence showed the foci of γH2AX in PTEN-WT BT549 cells treated with 5 μM olaparib (OLA), 5 μM RI-1, and their combination. B. The quantification of immunofluorescenct results. *p ≤ 0.05, ** p ≤ 0.01, ***p ≤ 0.001. C. MTT analysis of PTEN-WT BT549 treated with olaparib or olaparib in combining with RI-1. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. D. MTT analysis of PTEN-WT BT549 treated with IR-1 for 48 h.
|
|
| S8234 |
RS-1RS-1 is a RAD51-stimulatory compound, which increases the DNA binding activity of RAD51. It is an HDR(homology-directed repair) enhancer that enhances Cas9- and TALEN-mediated knock-in efficiency in rabbit embryos both in vitro and in vivo. |
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S1244 |
Amuvatinib (MP-470)Amuvatinib (MP-470, HPK 56) is a potent and multi-targeted inhibitor of c-Kit, PDGFRα and Flt3 with IC50 of 10 nM, 40 nM and 81 nM, respectively. Amuvatinib suppresses c-MET and c-RET. Amuvatinib is also active as a DNA repair protein Rad51 inhibitor with antineoplastic activity. Phase 2. |
Inactivation of AXL by MP470 reverses epithelial to mesenchymal transition. Immunoblot analyses of lysates from TGFβ/TNFα- treated MCF10A cells treated with varying amounts of MP470 for 72 hours.
|
|
| S2871 |
T0070907T0070907 is a potent and selective PPARγ inhibitor with IC50 of 1 nM in a cell-free assay, with a >800-fold selectivity over PPARα and PPARδ. T0070907 significantly decreases the levels of DNA-PKcs and RAD51 proteins in ME-180 and SiHa cells. |
Knocking down LKB1 reversed the PPARc antagonist T0070907-induced changes in the protein expression of the M1 markers (iNOS, green) and the M2 markers (CD206, red) by immunofluorescence staining. Scale bar = 20 μm.
|
|
| S8077 |
RI-1RI-1 (RAD51 inhibitor 1) is a RAD51 inhibitor with IC50 ranging from 5 to 30 μM. |
Inhibition of Rad51 sensitizes PTEN-WT BT549 cells to olaparib. A. Immunofluorescence showed the foci of γH2AX in PTEN-WT BT549 cells treated with 5 μM olaparib (OLA), 5 μM RI-1, and their combination. B. The quantification of immunofluorescenct results. *p ≤ 0.05, ** p ≤ 0.01, ***p ≤ 0.001. C. MTT analysis of PTEN-WT BT549 treated with olaparib or olaparib in combining with RI-1. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. D. MTT analysis of PTEN-WT BT549 treated with IR-1 for 48 h.
|
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S8234 |
RS-1RS-1 is a RAD51-stimulatory compound, which increases the DNA binding activity of RAD51. It is an HDR(homology-directed repair) enhancer that enhances Cas9- and TALEN-mediated knock-in efficiency in rabbit embryos both in vitro and in vivo. |
